Humanigen — Shareholder Meeting (June 2021)
13 slides from Humanigen's shareholder meeting presentation, Jun 17, 2021
Slide 1: Humanigen 2021 Annual Stockholder Meeting
Humanigen 2021 Annual Stockholder Meeting June 17
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation are forward - looking statements . Forward - looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding f
Slide 3: Humanigen Today: Company Highlights
3 Humanigen Today: Company Highlights Leading expertise in Hyper - inflammation and Cytokine Storm across multiple therapeutic applications ACTIV - 5/BET - B: 200 patient COVID - 19 (remdesivir +/ - lenzilumab ) NIH fully sponsored study enrolling LIVE - AIR: 520 patient Phase 3 registration study i
Slide 4: Experienced and Execution-Oriented Management
4 Experienced and Execution - Oriented Management Tim Morris, CPA – Chief Operating and Chief Financial Officer Retired CFO Iovance ; raised > $2.2Bn over 29 years Extensive deal experience with >90 transactions, combined value $4.8B 5 NDA/MAA and associated commercial prep and launch experien
Slide 5: Highly Credentialed and Engaged Board
5 Highly Credentialed and Engaged Board Rainer Boehm, MD, MBA Former interim CEO Novartis Pharma; Chief Commercial and Chief Medical Affairs Officer, Novartis Pharma; EVP, Novartis Oncology Board member Cellectis Ron Barliant , JD Of Counsel with Goldberg Kohn US bankruptcy judge for N. Illi
Slide 6: Clinical Pipeline
6 Clinical Pipeline Indication Phase Status Centers Partners Lenzilumab LIVE - AIR Prevention / treatment of Hyper - inflammation / Cytokine Storm 3 Completed (520 patients) EUA submitted 24 US 11 Brazil Company sponsored ACTIV - 5/BET - B Prevention / treatment of Hyper - inflammation / Cytokine St
Slide 7: Quick, Critical Focus on Cytokine Storm, as COVID Emerged, Transformed Our Company
7 Quick, Critical Focus on Cytokine Storm, as COVID Emerged, Transformed Our Company In March 2020, we identified lenzilumab as a potential treatment for COVID and quickly progressed to FDA protocol approval and first patient dosed (FPD) in just two months We rapidly enrolled and completed a trial o
Slide 8: COVID-Related Accomplishments
8 COVID - Related Accomplishments May 5 June 15 July 27 March 29 May 5 May 28 June 14 2020 2021 FPD in FDA - approved Phase 3 study Mayo Clinic manuscript published NIH selects lenzilumab for ACTIV - 5/Big Effect Trial Topline Phase 3 results from LIVE - AIR hit primary endpoint LIVE - AIR manuscrip
Slide 9: Other Accomplishments
9 Other Accomplishments September 18 September 20 November 20 December 22 April 9 April 19 June 21 June 28 Uplisted to Nasdaq Capital Market Reactivated wholly - owned subsidiary in UK Issuance of US patent in CAR - T Positive ifabotuzumab Phase 1 GBM 100% ORR Phase 1b CAR - T Created wholly - owned
Slide 10: Clinical Accomplishments Enabled Access to Capital
10 Clinical Accomplishments Enabled Access to Capital Our ability to successfully identify and demonstrate the potential clinical benefit of lenzilumab in COVID - 19 significantly improved our access to capital ▪ Private placement @ $4.35/share (reverse - split adjusted) raised ~$72MM gross ▪ Public
Slide 11: Financial Overview
11 Financial Overview Current Balance (MM) • Proforma post - Q1 cash equivalents $187 • Via Hercules, up to an additional $ 55 • Shares outstanding 59
Slide 12: Others are Following, But We Plan to Advance Our Lead
12 Others are Following, But We Plan to Advance Our Lead By Continuing to Invest in . . . □ Manufacturing with global leaders □ Preparing for commercialization □ Advancing clinical development and data in CAR - T, GvHD, CMML, COVID and non - COVID respiratory and other conditions □ Expanding our IP
Slide 13: Goals: Next Months
13 Goals: Next 12 Months □ Commercial scale manufacture of lenzilumab □ Commence commercialization in countries where lenzilumab use authorized/approved □ Announce data from ACTIV - 5/BET - B □ Submit lenzilumab Biologics License Application to FDA □ Initiate Phase 2 potential registrational CAR - T